Download PDFPDF
The New European Society of Cardiology guidelines on hypertrophic cardiomyopathy
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Increasing professional and societal awareness of the uncertainty underpinning hypertrophic cardiomyopathy (HCM)

    I read with great interest the above guidelines published for this rare inherited heart disorder. Over the past few years, much work has gone into elucidating possible risk factors and markers which can help predict sudden cardiac death in such patients. Namely, we have already established that myocardial fibrosis, age and certain mutations in cardiac genes are markers indicative of a higher risk of sudden cardiac death for t...

    Show More
    Conflict of Interest:
    None declared.